OhioHealth Partners with bioMérieux as Newest Global Antimicrobial Stewardship Center of Excellence
bioMérieux (OTC:BMXXY) has designated OhioHealth as the nation's newest Antimicrobial Stewardship (AMS) Center of Excellence, making it the 4th institution in the country and the first regional healthcare system to receive this recognition. The partnership aims to combat antimicrobial resistance (AMR), which is predicted to surpass cancer as the leading cause of death globally by 2050.
Through this collaboration, bioMérieux will provide expertise in advanced diagnostic technologies, IT and lab automation, along with training and quality management support. The OhioHealth Microbiology Laboratory will focus on early and accurate diagnostic testing to guide appropriate antibiotic use and improve patient outcomes across more than 50 of Ohio's 88 counties.
bioMérieux (OTC:BMXXY) ha nominato OhioHealth come il nuovo Centro di Eccellenza per la Stewardship Antimicrobica (AMS) negli Stati Uniti, diventando la 4ª struttura nel paese e il primo sistema sanitario regionale a ottenere questo riconoscimento. La collaborazione mira a contrastare la resistenza antimicrobica (AMR), stimata che potrebbe superare il cancro come principale causa di morte a livello mondiale entro il 2050.
Con questo partenariato, bioMérieux metterà a disposizione competenze in tecnologie diagnostiche avanzate, IT e automazione di laboratorio, oltre a supporto nella formazione e nella gestione della qualità. Il Laboratorio di Microbiologia di OhioHealth si concentrerà su test diagnostici precoci e accurati per orientare l'uso appropriato degli antibiotici e migliorare gli esiti clinici in oltre 50 delle 88 contee dell'Ohio.
bioMérieux (OTC:BMXXY) ha designado a OhioHealth como el nuevo Centro de Excelencia en Manejo de Antimicrobianos (AMS) del país, convirtiéndose en la 4.ª institución en Estados Unidos y el primer sistema sanitario regional en recibir este reconocimiento. La asociación busca combatir la resistencia antimicrobiana (AMR), prevista para superar al cáncer como principal causa de muerte a nivel mundial para 2050.
A través de esta colaboración, bioMérieux aportará experiencia en tecnologías diagnósticas avanzadas, TI y automatización de laboratorio, así como apoyo en capacitación y gestión de calidad. El Laboratorio de Microbiología de OhioHealth se enfocará en pruebas diagnósticas tempranas y precisas para orientar el uso adecuado de antibióticos y mejorar los resultados en pacientes en más de 50 de los 88 condados de Ohio.
bioMérieux (OTC:BMXXY)는 오하이오헬스(OhioHealth)를 미국의 새로운 항균제 관리(AMS) 우수센터로 지정했으며, 이는 미국 내 4번째 기관이자 첫 지역 의료 시스템으로서의 성과입니다. 이 파트너십은 항생제 내성(AMR)에 대응하는 것을 목표로 하며, AMR은 2050년까지 암을 제치고 전 세계 사망 원인 1위가 될 것으로 예측됩니다.
이번 협력을 통해 bioMérieux는 첨단 진단기술, IT 및 실험실 자동화에 대한 전문지식과 교육 및 품질관리 지원을 제공할 예정입니다. 오하이오헬스 미생물학 실험실은 조기 정확한 진단검사에 주력하여 적절한 항생제 사용을 안내하고, 오하이오의 88개 군 가운데 50곳 이상에서 환자 치료 성과를 개선할 것입니다.
bioMérieux (OTC:BMXXY) a désigné OhioHealth comme le nouveau Centre d'Excellence en Antimicrobial Stewardship (AMS) du pays, en faisant la 4e institution aux États‑Unis et le premier système de soins régional à recevoir cette distinction. Le partenariat vise à lutter contre la résistance aux antimicrobiens (AMR), qui devrait dépasse r le cancer comme principale cause de décès dans le monde d'ici 2050.
Dans le cadre de cette collaboration, bioMérieux apportera son expertise en technologies diagnostiques avancées, en informatique et automatisation de laboratoire, ainsi qu'un soutien en formation et gestion de la qualité. Le laboratoire de microbiologie d'OhioHealth se concentrera sur des tests diagnostiques précoces et précis pour guider l'utilisation appropriée des antibiotiques et améliorer les résultats pour les patients dans plus de 50 des 88 comtés de l'Ohio.
bioMérieux (OTC:BMXXY) hat OhioHealth als neues Antimikrobielles Stewardship (AMS) Center of Excellence in den USA benannt und damit die 4. Institution im Land sowie das erste regionale Gesundheitssystem ausgezeichnet. Die Partnerschaft zielt darauf ab, antimikrobielle Resistenz (AMR) zu bekämpfen, die voraussichtlich bis 2050 Krebs als häufigste Todesursache weltweit übertreffen wird.
Im Rahmen der Zusammenarbeit stellt bioMérieux Expertise in fortschrittlichen Diagnosetechnologien, IT und Laborautomatisierung sowie Unterstützung bei Schulung und Qualitätsmanagement bereit. Das Mikrobiologielabor von OhioHealth wird sich auf frühe und präzise Diagnostik konzentrieren, um den angemessenen Einsatz von Antibiotika zu steuern und die Patientenergebnisse in mehr als 50 der 88 Countys von Ohio zu verbessern.
- Recognition as the 4th AMS Center of Excellence in the US validates OhioHealth's leadership in patient care
- Partnership extends advanced diagnostic capabilities across 50+ Ohio counties
- Collaboration aims to reduce healthcare costs through optimized antibiotic use and decreased hospital stays
- None.
OhioHealth is only the 4th to receive the designation in the country, and the first regional healthcare system.
The bioMérieux AMS Center of Excellence initiative represents a unique set of health systems worldwide that share the same commitment as bioMérieux – to improve AMS and slow the spread of antimicrobial resistance (AMR), a growing global public health threat. This partnership recognizes the critical role of the laboratory in driving data-informed diagnostic practices to enhance patient care, advance infectious disease management, and accelerate the fight against AMR. OhioHealth is the first regional healthcare system in the AMS Center of Excellence network, covering more than 50 of the 88 counties in the state of
This partnership illustrates OhioHealth's commitment to setting the national standard on patient safety and positive outcomes. Leaning into its core values of excellence and stewardship, this collaboration supports the overall mission to improve the health of those OhioHealth serves through exceptional healthcare for all.
"OhioHealth is a national leader, providing exceptional, high-quality care for each patient we have the honor of serving," said Andrea K. Smith, M.S., MB(ASCP)CM OhioHealth Senior Director, Laboratory Services. "For our system microbiology laboratory to be recognized as an Antimicrobial Stewardship (AMS) Center of Excellence by bioMérieux, it serves as validation for what we have passionately worked to achieve. We always put patients at the center of everything we do. By utilizing innovative technologies and best practices, we will continue to lead, ensuring our patients have the best possible outcomes."
No one is safe from AMR. By 2050, AMR is predicted to surpass cancer as the leading cause of death globally.1 Early and accurate diagnostic testing, the mission of the OhioHealth Microbiology Laboratory, plays a pivotal role in guiding appropriate antibiotic use, reducing unnecessary prescriptions, and improving patient outcomes. Economically, diagnostics can reduce healthcare costs by minimizing the use of broad-spectrum antibiotics and, most importantly, decreasing hospital stays and readmissions.
"Diagnostics are among the most powerful tools we have in the fight against AMR," said Jennifer Zinn, bioMérieux Executive Vice President of Clinical Operations. "Advancing AMS requires collaboration across the entire healthcare ecosystem—from clinicians, lab professionals, pharmacists, and beyond. We're honored to welcome OhioHealth to this global movement of forward-thinking health systems. By leveraging our collective expertise and embracing diagnostics-driven stewardship, we can accelerate meaningful change, harness innovation, and ultimately help improve patient outcomes."
Through the partnership, bioMérieux will provide its expertise in advanced diagnostic technologies, IT and lab automation, as well as training and quality management support. A dedicated bioMérieux Center of Excellence team will support OhioHealth with its unique AMS initiatives to optimize these high-value solutions to improve patient care and mitigate the spread of AMR.
ABOUT GLOBAL ANTIMICROBIAL STEWARDSHIP AND AMS CENTERS OF EXCELLENCE
In 2021, bioMérieux established the Antimicrobial Stewardship Centers of Excellence program to bring attention to the threat of antimicrobial resistance and to accelerate the impact that infectious diseases diagnostics have in facilitating antimicrobial stewardship and better patient care. OhioHealth is the fourth
According to a landmark study published in The Lancet in 2022, as of 2019, an estimated 4.95 million annual deaths were associated with bacterial AMR, with 1.27 million deaths directly attributable to it.2 In the
To learn more about the AMS Centers of Excellence program, visit www.biomerieux.com/corp/en/our-offer/strategic-partnerships/ams-centers-of-excellence.html.
References:
- O'Neill, Jim, Tackling drug-resistant infections globally: Final report and recommendations. Review on Antimicrobial Resistance.
London, UK ., 2016 May - Murray, Christopher J L et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet. 2022 Feb.
- Amin VP, Dhanani M, Patel J, Dhawan A, Mahesh G, Chenna VSH, Kyada S, Dekhne A, Desai HD. 2233. Burden of Bacterial Antimicrobial Resistance in
United States in 2019: A Systematic Analysis. Open Forum Infect Dis. 2023 Nov 27;10(Suppl 2): ofad500.1855.
ABOUT BIOMÉRIEUX
Pioneering Diagnostics
A world leader in the field of in vitro diagnostics for 60 years, bioMérieux is present in 45 countries and serves more than 160 countries with the support of a large network of distributors. In 2024, revenues reached
bioMérieux is listed on the Euronext Paris stock market.
Symbol: BIM – ISIN Code: FR0013280286
Reuters: BIOX.PA/Bloomberg: BIM.FP
Corporate website: www.biomerieux.com
ABOUT OHIOHEALTH
Based in
Serving its communities since 1891, OhioHealth is a family of 35,000 associates, physicians and volunteers, and a network of 16 hospitals, three joint-venture hospitals, 200+ ambulatory sites and other health services spanning a 50-county area. It has been recognized by FORTUNE as one of the "100 Best Companies to Work For" 15 times since 2007. For more information, visit ohiohealth.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/ohiohealth-partners-with-biomerieux-as-newest-global-antimicrobial-stewardship-center-of-excellence-302539195.html
SOURCE bioMérieux; OhioHealth
FAQ
What is the significance of OhioHealth's partnership with bioMérieux (BMXXY)?
How many counties will be covered under the OhioHealth and bioMérieux (BMXXY) partnership?
What support will bioMérieux (BMXXY) provide to OhioHealth under this partnership?
What is the projected impact of antimicrobial resistance (AMR) according to the bioMérieux announcement?
How will the bioMérieux (BMXXY) partnership help reduce healthcare costs?
